December 23, 2016
FMR LLC shareholding in Ablynx slightly increases
Ablynx has received a notification of shareholdings from FMR LLC, according to which its stake in Ablynx has slightly increased.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
December 22, 2016
ImmuPharma recruits patients for Phase III study of Lupuzor
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…
December 22, 2016
Biocartis submits 510(k) to FDA, expands European hospitals deal with Amgen
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
December 22, 2016
Abzena in licence agreement with USA-based Trieza
Abzena has granted USA-based Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, for exploitation in…
December 22, 2016
Advanced Oncotherapy happy with technical development of the LIGHT system
Advanced Oncotherapy has successfully tested and calibrated programme at ADAM in Geneva, and that made it possible to integrate the…
December 22, 2016
Horizon’s lung infections antibiotic Quinsair available in Canada for adults with Cystic Fibrosis
Horizon Pharma and its Canadian affiliate Horizon Therapeutics Canada Limited have brought its inhalation solution for chrnic lung infection Quinsair to Canada.
Quinsair is used for chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).
December 22, 2016
Allergan/Ironwood’s enhanced linaclotide CR1 could double Linzess franchise from $1B in U.S. net sales by 2020
Ironwood Pharmaceuticals and Allergan have been testing an irritable bowel syndrome with constipation (IBS-C) drug, a formulation of linaclotide colonic…
December 22, 2016
FDA accepts Pfizers breast cancer drug supplemental New Drug Application
Pfizer is moving forward with Ibrance breast cancer drug as the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA).
December 21, 2016
Janssen asks FDA approval for psoriatic arthritis drug
Janssen Biotech has submitted two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval…
December 21, 2016
BMS and Calithera Biosciences team up against cancer
Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule…